My Cart

0 Item(s): $0.00

You have no items in your shopping cart.

Voglibose

Voglibose

Description

Voglibose 0.3 MG Tablet is used to lower blood glucose level in patients with Type 2 Diabetes Mellitus, especially when other medicines are not able to provide the desired results. It belongs to a group of medicines known as alpha-glucosidases inhibitors.

Voglibose Reduces Occurrence Of Type 2 Diabetes In High Risk Japanese People

Together with lifestyle changes, the drug Voglibose reduces the progress of type 2 diabetes in high-risk Japanese people. Professor Ryuzo Kawamori, from the Juntendo University School of Medicine, in Tokyo, Japan, and his colleagues report their findings in an article published Online First and in a future edition of The Lancet.

Voglibose, a α-glucosidase inhibitor, lowers the amount of glucose absorbed into the bloodstream. The randomized trial included 1,780 eligible participants that showed signs of impaired glucose tolerance, but not full-blown diabetes. 897 were assigned daily three oral doses of 0.2mg of voglibose, and the remaining 883 received a placebo. All participants maintained a regular diet and performed routine exercise. Treatment was continuous for a minimum of three years or until participants developed either type 2 diabetes or normal blood sugar control (normoglycaemia).

The study shows that after one year of treatment, participants consuming voglibose had more effective results than those on the placebo, having a 40 percent lower risk of developing type 2 diabetes and 54 percent more likely to reach normoglycaemia. Probably associated with the treatment, there were adverse effects on 48 percent of the participants with voglibose compared to only 29 percent in the placebo group. However, in both groups there were reports of some serious adverse events. In the voglibose group, there was a gall bladder inflammation, a colonic polyp, a rectal tumor, an inguinal hernia, a liver dysfunction and a brain hemorrhage. In the placebo group there was a report of a blockage of brain blood-flow and a swelling of a gall-bladder.

Side effects

  • Diarrhea
  • Flatulence
  • Pneumatosis Intestinalis
  • Abnormal liver function
  • Nausea or vomiting
  • Dizziness

Why is Voglibose Prescribed? (Indications)

This medication is an alpha-glucosidase inhibitor, prescribed for diabetes mellitus. 

Methods

Healthy male wistar rats weighing 150-250 grams were taken for this study. The animals were divided into five groups, six animals in each group. These groups were normal control, diabetic control, vildagliptin treated, voglibose treated and by vildagliptin and voglibose (co-administered) treated group diabetic rats. Diabetes was induced by freshly prepared nicotinamide followed by streptozotocin intraperitoneal injection. The fasting blood samples were determined by glucose oxidase method. One way ANOVA test was used to compare the effect of drugs on different group.

Results

Fasting blood glucose in normal control was found static. Diabetic rats fasting blood glucose level subsequently increased in different weeks. The animal treated by vildagliptin and voglibose orally has a better control of FBS in comparison to diabetic control group. The animal treated by co-administration of vildagliptin and voglibose had a better effect than vildagliptin treated group and voglibose treated animal.

 

Loading...